Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.80
-0.26 (-1.65%)
At close: Mar 6, 2026, 4:00 PM EST
15.80
+0.01 (0.03%)
After-hours: Mar 6, 2026, 5:40 PM EST
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 28, with a low estimate of 11 and a high estimate of 42. The average target predicts an increase of 77.27% from the current stock price of 15.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $13 → $42 | Strong Buy | Maintains | $13 → $42 | +165.91% | Jan 22, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $32 | Buy | Maintains | $15 → $32 | +102.60% | Jan 21, 2026 |
| Barclays | Barclays | Buy Maintains $16 → $28 | Buy | Maintains | $16 → $28 | +77.27% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $27 | Strong Buy | Maintains | $11 → $27 | +70.94% | Jan 20, 2026 |
| Barclays | Barclays | Buy Initiates $16 | Buy | Initiates | $16 | +1.30% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.21
from -1.02
EPS Next Year
-0.62
from -0.21
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.12 | -0.44 | ||||
| Avg | -0.21 | -0.62 | ||||
| Low | -0.52 | -0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.